Magazine - 28 Apr 2022 | Shares Magazine

Menu

Magazine
- Back
- Latest Issue: 21 Nov 2024
- Archives
  
  14 Nov 2024
  
  07 Nov 2024
  
  31 Oct 2024
  
  24 Oct 2024
  View all
- More Reading
Tools
- Back
- Market Data
  - Back
  - Share Prices
  - Indices
  - Funds
  - Forex
  - IPOs
  - Market Diary
- Market Tools
  - Back
  - Portfolio
  - Stockwatch
  - Market Scan
  - Charts
  - Alerts
- Director Deals
  - Back
  - Director Deals
  - Latest Deals
  - Analysis
  - Search
  - Alerts
News
- Back
- Shares News
  Shares journalists news and views on today's breaking stories.
- Market & Company News
  A comprehensive daily news service of over 300 market and company stories from Alliance News and the RNS.
Awards
- Back
- Investment Awards
  
  The AJ Bell Investment Awards is your chance to vote for your pick of active and passive funds.
Events
- Back
- Upcoming Events
  
  Shares Investor Webinar
  
  Tuesday 26 November 2024
  
  The webinar will feature the following companies: Henderson International Income Trust and NB Private Equity
  
  Shares Investor Evening (London) - LIVE EVENT
  
  Novotel Tower Bridge, EC3N 2NR
  
  Wednesday 4 December 2024
  
  This event will feature the following companies: Selkirk, Shepherd Neame, Strix and Target Healthcare REIT
  
  Retirement Money Show - Growth
  
  America Square Conference Centre, EC3N 2LB
  
  Monday 9 December 2024
  
  The event will feature the following companies: AJ Bell, Bankers Investment Trust, Scottish Mortgage Investment Trust, abrdn Smaller Companies Growth Trust, Schroder AsiaPacific Fund, Polar...
  
  Retirement Money Show - Income
  
  America Square Conference Centre, EC3N 2LB
  
  Tuesday 10 December 2024
  
  The event will feature the following companies: AJ Bell, JPMorgan Global Growth and Income, Greencoat UK Wind, Law Debenture, Invesco Bond Income Plus and CT Private Equity Trust.
  
  Previous Events
- Previous Events
Videos
Podcasts
Contact us and help Subscribe

Archives
Magazine - 28 Apr 2022

Shares Magazine Cover Image

Download Read now

The ability to put up prices without losing customers is such a valuable trait right now and the latest issue of Shares highlights companies with this pricing power.

Plus, the quality names which have been caught up in the tech sell-off, why one investment bank thinks oil prices could surge 30% and the stocks trading at 52-week highs and lows.

Discover some reasons to be cheerful about your money, why Coca-Cola impressed and the small cap in which consumer goods giant Unilever has a more than 10% stake.

Great Ideas

Strong reasons to buy Strix, a global leader in niche market

Dominant in its core kettle controls space, there is substantial scope for acquisitions to bolster growth

News

Novacyt faces £134.6 million NHS legal claim

Despite a difficult time for the shares over the last year they are still up around 10-fold since the start of the pandemic

News

Can consumer-facing firms beat the big squeeze?

Consumer goods groups and retailers are raising prices but there’s a limit to the number of hikes cash-strapped shoppers can stomach

News

Growth stocks continue to struggle as we reveal stocks at 52-week highs and lows

Real assets have so far provided the best defence against higher rates and inflation

News

Shares in mining companies hurt by Chinese lockdowns and operational issues

Sector under pressure as Beijing continues to pursue zero-Covid approach, threatening commodities demand

Great Ideas

Loungers maintains fast growth despite facing consumer headwinds

Loungers’ all-day trading format and value for money offering positions it well for the future

Great Ideas

Brookfield and Homeserve in talks as broker says shares could be worth £15

Business services firm moves closer to private equity takeover

Great Ideas

Asia Dragon Trust goes shopping for stocks amid market sell-off

The investment trust outperformed its benchmark over the past half-year

Great Ideas

Smartly-timed sale and share buyback reveal Spectris’ hidden value

Sensor and controls firm shows it is very smart when it comes to allocating its resources

Great Ideas

Why B&M remains a great way to beat the squeeze

Share price reversal on CEO retirement news and retail sector read-across seems overdone

News

Why language services group RWS could be the latest private equity victim

Davy estimates over 25% of RWS’s market cap would be represented by net cash in 2026

Editor's View

There could be more pain to endure from rising oil prices

Morgan Stanley believes oil prices could be 30% higher in a matter of months

Personal Finance

Here are some reasons to be more cheerful about your money

Times may be tough but several things have improved when it comes to managing your finances

Feature

Great buying opportunities from the big tech rout

We identify three stocks with excellent recovery and growth potential

Funds

The majority of absolute return funds have lost investors money this year

These products are designed to deliver whatever the weather but plenty are not proving their worth

Feature

The companies able to charge more without hurting demand

The recent surge in inflationary pressure threatens corporate margins, profits and investor returns but companies with pricing power are well positioned to deal with this backdrop

Feature

Explaining the poison pill defence which could have derailed Musk’s Twitter bid

US corporate poison pills give boards power over who owns the business

Feature

How big property funds have performed and the different ways to invest

Vehicles investing in warehouses and self-storage have done pretty well despite the gloomy headlines

Ask Tom

I’m retiring to the UK from overseas can I set up a SIPP?

A Canadian heading to these shores asks about opening a private pension

Feature

Emerging markets: Views from the experts

Three things the Franklin Templeton Emerging Markets Equity team are thinking about today

Feature

The best and worst first quarter performers in emerging markets

Taking stock of markets in the developing world in the first quarter of 2022

Feature

Why Unilever has a 10.5% stake in this small cap drug developer

AIM-quoted Arecor Therapeutics has a track record of partnering up with big pharma firms